Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2011 | Research

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

Authors: Cheryl A Sherman-Baust, Kevin G Becker, William H Wood III, Yongqing Zhang, Patrice J Morin

Published in: Journal of Ovarian Research | Issue 1/2011

Abstract

Background

Resistance to current chemotherapeutic agents is a major cause of therapy failure in ovarian cancer patients, but the exact mechanisms leading to the development of drug resistance remain unclear.

Methods

To better understand mechanisms of drug resistance, and possibly identify novel targets for therapy, we generated a series of drug resistant ovarian cancer cell lines through repeated exposure to three chemotherapeutic drugs (cisplatin, doxorubicin, or paclitaxel), and identified changes in gene expression patterns using Illumina whole-genome expression microarrays. Validation of selected genes was performed by RT-PCR and immunoblotting. Pathway enrichment analysis using the KEGG, GO, and Reactome databases was performed to identify pathways that may be important in each drug resistance phenotype.

Results

A total of 845 genes (p < 0.01) were found altered in at least one drug resistance phenotype when compared to the parental, drug sensitive cell line. Focusing on each resistance phenotype individually, we identified 460, 366, and 337 genes significantly altered in cells resistant to cisplatin, doxorubicin, and paclitaxel, respectively. Of the 845 genes found altered, only 62 genes were simultaneously altered in all three resistance phenotypes. Using pathway analysis, we found many pathways enriched for each resistance phenotype, but some dominant pathways emerged. The dominant pathways included signaling from the cell surface and cell movement for cisplatin resistance, proteasome regulation and steroid biosynthesis for doxorubicin resistance, and control of translation and oxidative stress for paclitaxel resistance.

Conclusions

Ovarian cancer cells develop drug resistance through different pathways depending on the drug used in the generation of chemoresistance. A better understanding of these mechanisms may lead to the development of novel strategies to circumvent the problem of drug resistance.

Available only for authorised users

Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: Cancer J Clin 2011, 61: 212–236. 10.3322/caac.20121

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334: 1–6. 10.1056/NEJM199601043340101PubMedCrossRef

Markman M: Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: time for an evidence-based comparison. Gynecol Oncol 2010, 118: 6–7. 10.1016/j.ygyno.2010.03.017PubMedCrossRef

Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3: 502–516. 10.1038/nrc1123PubMedCrossRef

Ishida S, Lee J, Thiele DJ, Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002, 99: 14298–14302. 10.1073/pnas.162491399PubMedCentralPubMedCrossRef

Ishida S, McCormick F, Smith-McCune K, Hanahan D: Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17: 574–583. 10.1016/j.ccr.2010.04.011PubMedCentralPubMedCrossRef

Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27: 5511–5526. 10.1038/onc.2008.246PubMedCrossRef

Yan X, Fraser M, Qiu Q, Tsang BK: Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol 2006, 102: 348–355. 10.1016/j.ygyno.2005.12.033PubMedCrossRef

Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D: Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer letters 2008, 271: 260–271. 10.1016/j.canlet.2008.06.012PubMedCrossRef

10.

Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, Timorek A, Dansonka-Mieszkowska A, Kupryjanczyk J: PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol & Ther 2009, 8: 21–26. 10.4161/cbt.8.1.7209CrossRef

11.

Shahzad MM, Lopez-Berestein G, Sood AK: Novel strategies for reversing platinum resistance. Drug Resist Updat 2009, 12: 148–152. 10.1016/j.drup.2009.09.001PubMedCentralPubMedCrossRef

12.

Gleichmann M, Zhang Y, Wood WH, Becker KG, Mughal MR, Pazin MJ, van Praag H, Kobilo T, Zonderman AB, Troncoso JC, et al.: Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiol Aging 2012, 33: 205 e201–205 e218.

13.

Cheadle C, Vawter MP, Freed WJ, Becker KG: Analysis of microarray data using Z score transformation. J Mol Diagn 2003, 5: 73–81. 10.1016/S1525-1578(10)60455-2PubMedCentralPubMedCrossRef

14.

Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ: Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 2009, 9: 244. 10.1186/1471-2407-9-244PubMedCentralPubMedCrossRef

15.

Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al.: Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 2011, 39: D691–697. 10.1093/nar/gkq1018PubMedCentralPubMedCrossRef

16.

Gordon AN, Tonda M, Sun S, Rackoff W: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95: 1–8. 10.1016/j.ygyno.2004.07.011PubMedCrossRef

17.

Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2: 48–58. 10.1038/nrc706PubMedCrossRef

18.

Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, et al.: Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. The Prostate 1999, 38: 118–125. 10.1002/(SICI)1097-0045(19990201)38:2<118::AID-PROS5>3.0.CO;2-GPubMedCrossRef

19.

Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA: A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res 2004, 64: 5370–5377. 10.1158/0008-5472.CAN-04-0788PubMedCrossRef

20.

Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA: Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anti-cancer drugs 2005, 16: 1045–1051. 10.1097/00001813-200511000-00002PubMedCrossRef

21.

Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, et al.: Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 2007, 26: 618–632. 10.1038/sj.onc.1209821PubMedCrossRef

22.

Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, Disaia P, Gabra H, Glenn P, et al.: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474: 609–615. 10.1038/nature10166CrossRef

23.

Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5: 219–234. 10.1038/nrd1984PubMedCrossRef

24.

Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV: Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003, 9: 2778–2785.PubMed

25.

Frisch SM, Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 2001, 13: 555–562. 10.1016/S0955-0674(00)00251-9PubMedCrossRef

26.

Sherman-Baust CA, Weeraratna AT, Rangel LBA, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ: Remodeling of the Extracellular Matrix Through Overexpression of Collagen VI Contributes to Cisplatin Resistance in Ovarian Cancer Cells. Cancer Cell 2003, 3: 377–386. 10.1016/S1535-6108(03)00058-8PubMedCrossRef

27.

Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, et al.: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999, 5: 662–668. 10.1038/9511PubMedCrossRef

28.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002, 99: 14374–14379. 10.1073/pnas.202445099PubMedCentralPubMedCrossRef

29.

Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, et al.: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9: 1136–1144.PubMed

30.

Ling YH, el-Naggar AK, Priebe W, Perez-Soler R: Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 1996, 49: 832–841.PubMed

31.

Mendelsohn AR, Hamer JD, Wang ZB, Brent R: Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death. Proc Natl Acad Sci USA 2002, 99: 6871–6876. 10.1073/pnas.072290599PubMedCentralPubMedCrossRef

32.

Del Prete MJ, Robles MS, Guao A, Martinez AC, Izquierdo M, Garcia-Sanz JA: Degradation of cellular mRNA is a general early apoptosis-induced event. FASEB J 2002, 16: 2003–2005.PubMed

33.

Chandra J, Samali A, Orrenius S: Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 2000, 29: 323–333. 10.1016/S0891-5849(00)00302-6PubMedCrossRef

Title: Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
Authors: Cheryl A Sherman-Baust
Kevin G Becker
William H Wood III
Yongqing Zhang
Patrice J Morin
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2011
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-4-21

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression

Hematopoietic-Prostaglandin D2 synthase through PGD2 production is involved in the adult ovarian physiology

Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation

MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines

Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)

Reinterpretation of evidence advanced for neo- oogenesis in mammals, in terms of a finite oocyte reserve